Tylan Soluble Powder for Oral Solution

Nchi: Ayalandi

Lugha: Kiingereza

Chanzo: HPRA (Health Products Regulatory Authority)

Viambatanisho vya kazi:

Tylosin (as tylosin tartrate)

Inapatikana kutoka:

Elanco GmbH

ATC kanuni:

QJ01FA90

INN (Jina la Kimataifa):

Tylosin (as tylosin tartrate)

Kipimo:

100 gram(s)

Dawa fomu:

Powder for oral solution

Dawa ya aina:

POM: Prescription Only Medicine as defined in relevant national legislation

Eneo la matibabu:

tylosin

Idhini hali ya:

Authorised

Idhini ya tarehe:

1988-10-01

Tabia za bidhaa

Health Products Regulatory Authority
02 August 2018
CRN000YJT
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Tylan Soluble Powder for Oral Solution
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
Tylosin 100g activity per bottle as Tylosin Tartrate.
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Powder for oral solution. A white to medium yellow powder.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Tylan Soluble is indicated for use in calves, pigs and poultry.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the control of _Mycoplasma synoviae _airsacculitis in chickens and
_Mycoplasma _
_gallisepticum _S6 in chickens and turkeys. In the field tylosin has
also proved useful in
reducing the level of infection following stress associated with live
vaccination.
As an aid in the control of outbreaks of necrotic enteritis in
chickens caused by
_Clostridium perfringens._
For the prevention and control of enzootic pneumonia, and scours
caused by
organisms (e.g. _Lawsonia intracellularis_) sensitive to tylosin, in
pigs.
For the control of pneumonia in cattle associated with mycoplasmata
and _Pasteurella_
_multocida _sensitive to tylosin.
For information regarding swine dysentery see section 4.5.
4.3 CONTRAINDICATIONS
Do not leave or dispose of water containing tylosin tartrate where it
may be
accessible to either animals not under treatment or wildlife.
Do not use in animals with known hypersensitivity to tylosin or other
macrolides.
Health Products Regulatory Authority
02 August 2018
CRN000YJT
Page 2 of 6
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Use of this product should be based on susceptibility testing of the
bacteria isolated
from the animal. If this is not possible, therapy should be based on
local (regional,
farm level) epidemiological information about susceptibility of the
target bacteria.
Whenever possible the product should only be used on the b